Development and evaluation of lipid nanoparticles for paclitaxel delivery: a comparison between solid lipid nanoparticles and nanostructured lipid carriers

Journal of Pharmaceutical Investigation

Volumn 45, Issue 7, 2015, Pages 675-680

  Xu, Wenting ^a   Lee, Mi Kyung ^a  

^a Woosuk University   (South Korea)

Author keywords

Cytotoxity; NLCs; Paclitaxel; SLNs

Indexed keywords

PACLITAXEL; SOLID LIPID NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENCAPSULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOCCULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MTT ASSAY; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL;

EID: 84948972937     PISSN: 20935552     EISSN: 20936214     Source Type: Journal    
DOI: 10.1007/s40005-015-0224-x     Document Type: Article

References (16)

1. Ceruti M, Crosasso P, Brusa P, Arpicco S, Dosio F, Cattel L (2000) Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel. J Control Release 63(1–2):141–153
2. Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G (2004) Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm 278(1):119–131
3. Darren LS, Nichols JW, Miura S, Bae YH (2013) Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J. Control Release 28:1045–1064
4. Dong X, Mattingly CA, Tseng M, Cho M, Adams VR, Mumper RJ (2009) Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization. Eur J Pharm Biopharm 72(1):9–17
5. Emami J, Rezazadeh M, Varshosaz J, Tabbakhian M, Aslani A (2012) Formulation of LDL targeted nanostructured lipid carriers loaded with paclitaxel: a detailed study of preparation, freeze drying condition, and in vitro cytotoxicity. Journal of nanomaterials. doi:10.1155/2012/358782
6. Feng L, Mumper RJ (2013) A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett 334(2):157–175
7. Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37(13):1590–1598
8. Hippalgaonkar K, Majumdar S, Kansara V (2010) Injectable lipid emulsions: advancements, opportunities and challenges. AAPS Pharm Sci Tech 11(4):1526–1540
9. Lee MK, Lim SJ, Kim CK (2007) Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 28:2137–2146
10. Ma P, Mumper RJ (2013) Paclitaxel nano-delivery systems: a comprehensive review. J Nanomed Nanotechnol 4(2):1000164
11. Muller RH, Radtke M, Wissing SA (2002) Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 242(1–2):121–128
12. Patil Y, Swaminathan S, Sadhukha T, Ma L, Panyam J (2010) The use of nanoparticles-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31(2):358–365
13. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, Blumenthal R (2009) Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst 26(6):523–580
14. Schwarz C, Mehnert W, Lucks JS, Müller RH (1994) Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release 30:83–96
15. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY (2007) Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 59(6):491–504
16. Zhang XG, Miao J, Dai YQ, Du YZ, Yuan H, Hu FQ (2008) Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int J Pharm 361(1–2):239–244